Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

13therapeutics Inc
AIM ImmunoTech Inc
Aston Sci Co Ltd
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Tollys SAS
Wyvern Pharmaceuticals Inc
Yisheng Biopharma Co Ltd